Long-Term Extension Study for Adults with Advanced Solid Tumors or Von Hippel-Lindau Disease Receiving Belzutifan Treatment

What this Trial Is About

Researchers are evaluating the long-term effects of belzutifan, a medicine designed to block a protein that helps tumors grow, in people with advanced solid tumors or tumors related to von Hippel-Lindau VHL disease. Advanced tumors are those that have spread or cannot be removed by surgery. This extension study includes participants who were already receiving belzutifan in certain parent trials to understand how long they live after starting the treatment. Participants who were on active treatment in a parent belzutifan study will continue the same dose and frequency of belzutifan or other therapies they were receiving when they join this extension study. Treatments include belzutifan alone, belzutifan combined with other drugs such as nivolumab, lenvatinib, or cabozantinib, or non-belzutifan therapies. Treatment continues until the disease worsens, unacceptable side effects occur, consent is withdrawn, death, investigator decision, or study ends. During the study, participants will be monitored for overall survival for up to approximately 7 years. Researchers will also track any adverse events and reasons for stopping treatment for up to about 2 years. Participants will have regular assessments and follow-ups to collect information on their health and response to treatment throughout the study period.

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)